Group 1 - The core point of the article is that ST Xiangxue announced the decision to abolish its supervisory board and the related rules during its board meeting held on November 28, 2025 [1] - The company reported its revenue composition for the first half of 2025, with traditional Chinese medicine accounting for 64.87%, pharmaceutical manufacturing for 22.53%, other sectors for 20.22%, pharmaceutical distribution for 4.27%, and medical devices for 1.18% [1] - As of the report, ST Xiangxue has a market capitalization of 6.3 billion yuan [1]

Core Viewpoint - ST Xiangxue announced the convening of its 31st meeting of the 9th board of directors on October 27, 2025, to review the full report for the third quarter of 2025 [1] Company Summary - For the first half of 2025, ST Xiangxue's revenue composition is as follows: Traditional Chinese medicine accounts for 64.87%, pharmaceutical manufacturing for 22.53%, other sectors for 20.22%, pharmaceutical distribution for 4.27%, and medical devices for 1.18% [1] - As of the report, ST Xiangxue has a market capitalization of 6.8 billion yuan [1]